We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MANH:NASDAQManhattan Associates, Inc. Analysis

Data as of 2026-06-30 - not real-time

$138.10

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Manhattan Associates is trading well above its intrinsic estimate, with the market price sitting on a clear premium to the discounted cash‑flow fair value. The stock shows a neutral technical stance: the 20‑day and 50‑day SMAs are nearly flat, RSI hovers around the midpoint, and the MACD histogram remains in negative territory, signalling limited short‑term upside. Volume is picking up, but the broader trend remains neutral and volatility is unusually high, reflecting heightened investor sensitivity. Recent news highlights a push into AI‑driven platforms and an ongoing investigation into fiduciary duties, adding both growth intrigue and governance risk. Fundamentals remain strong, with solid revenue growth, high gross margins, and a remarkable return on equity, yet the lack of dividend payout and a price that exceeds comparable industry multiples suggest the market may be pricing in future expectations rather than current performance.
Given the sizeable upside indicated by valuation models, a medium‑term view leans bullish, especially if the AI initiatives translate into measurable revenue. However, the current overvaluation, bearish MACD signal, and regulatory scrutiny temper short‑term confidence. Long‑term investors may find the company attractive for its high profitability and growth trajectory, provided they can tolerate the near‑term valuation premium and governance uncertainties.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bearish MACD histogram indicates limited near‑term momentum
  • Elevated volatility raises downside risk
  • Ongoing fiduciary‑duty investigation adds governance uncertainty

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • AI‑centric ActivePlatform could unlock new revenue streams
  • Strong operating margins and high ROE support earnings growth
  • Valuation model shows meaningful upside relative to current price

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Sustained high profitability and cash‑flow generation
  • Expanding global footprint across multiple verticals
  • Potential for the AI initiatives to become a core growth engine by 2027

Key Metrics & Analysis

Financial Health

Revenue Growth7.40%
Profit Margin19.68%
P/E Ratio38.6
ROE96.24%
ROA24.29%
Debt/Equity27.14
P/B Ratio39.8
Op. Cash Flow$398.3M
Free Cash Flow$295.0M
Industry P/E36.9

Technical Analysis

TrendNeutral
RSI49.8
Support$126.35
Resistance$162.77
MA 20$141.43
MA 50$139.45
MA 200$161.13
MACDBearish
VolumeIncreasing
Fear & Greed Index89.91

Valuation

Fair Value$94.30
Target Price$184.00
Upside/Downside33.24%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.81
Volatility48.31%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.